{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:41:42Z","timestamp":1744166502405},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,9,6]],"date-time":"2005-09-06T00:00:00Z","timestamp":1125964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00262-005-0050-5","type":"journal-article","created":{"date-parts":[[2005,9,8]],"date-time":"2005-09-08T13:16:37Z","timestamp":1126185397000},"page":"653-662","source":"Crossref","is-referenced-by-count":9,"title":["Interferon-\u03b3 renders tumors that express low levels of Her-2\/neu sensitive to cytotoxic T cells"],"prefix":"10.1007","volume":"55","author":[{"given":"Barbara L. F.","family":"Kaplan","sequence":"first","affiliation":[]},{"given":"H\u00e5kan","family":"Norell","sequence":"additional","affiliation":[]},{"given":"Glenda G.","family":"Callender","sequence":"additional","affiliation":[]},{"given":"Tomas","family":"Ohlum","sequence":"additional","affiliation":[]},{"given":"Rolf","family":"Kiessling","sequence":"additional","affiliation":[]},{"given":"Michael I.","family":"Nishimura","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,9,6]]},"reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-4827(02)00099-X","volume":"284","author":"T Holbro","year":"2003","unstructured":"Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99\u2013110","journal-title":"Exp Cell Res"},{"key":"50_CR2","first-page":"2420","volume":"61","author":"I Hellstrom","year":"2001","unstructured":"Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE (2001) Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61:2420\u20132423","journal-title":"Cancer Res"},{"key":"50_CR3","first-page":"1027","volume":"7","author":"E Liu","year":"1992","unstructured":"Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C (1992) The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027\u20131032","journal-title":"Oncogene"},{"key":"50_CR4","unstructured":"Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ (1990) HER-2\/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 209\u2013221"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O","volume":"87","author":"B Seliger","year":"2000","unstructured":"Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S, Kiessling R (2000) HER-2\/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 87:349\u2013359","journal-title":"Int J Cancer"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000227222","volume":"50","author":"K Tsugawa","year":"1993","unstructured":"Tsugawa K, Fushida S, Yonemura Y (1993) Amplification of the c-erbB-2 gene in gastric carcinoma:correlation with survival. Oncology 50:418\u2013425","journal-title":"Oncology"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","volume":"11","author":"R Seshadri","year":"1993","unstructured":"Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936\u20131942","journal-title":"J Clin Oncol"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285\u20134289","journal-title":"Proc Natl Acad Sci USA"},{"key":"50_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","volume":"8","author":"JS Ross","year":"2003","unstructured":"Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307\u2013325","journal-title":"Oncologist"},{"key":"50_CR11","first-page":"4902","volume":"58","author":"TZ Zaks","year":"1998","unstructured":"Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369-377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors. Cancer Res 58:4902\u20134908","journal-title":"Cancer Res"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1084\/jem.181.6.2109","volume":"181","author":"B Fisk","year":"1995","unstructured":"Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109\u20132117","journal-title":"J Exp Med"},{"key":"50_CR13","first-page":"1071","volume":"54","author":"ML Disis","year":"1994","unstructured":"Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA (1994) In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2\/neu protooncogene protein. Cancer Res 54:1071\u20131076","journal-title":"Cancer Res"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-003-0420-9","volume":"52","author":"PA Sotiropoulou","year":"2003","unstructured":"Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN (2003) Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2\/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 52:771\u2013779","journal-title":"Cancer Immunol Immunother"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1097-0215(19970106)70:1<112::AID-IJC17>3.0.CO;2-N","volume":"70","author":"K Kono","year":"1997","unstructured":"Kono K, Halapi E, Hising C, Petersson M, Gerdin E, Vanky F, Kiessling R (1997) Mechanisms of escape from CD8+ T-cell clones specific for the HER-2\/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int J Cancer 70:112\u2013119","journal-title":"Int J Cancer"},{"key":"50_CR16","first-page":"14","volume":"2","author":"PL Lollini","year":"1985","unstructured":"Lollini PL, Colombo MP, De Giovanni C, Nicoletti G, Parmiani G, Prodi G, Nanni P (1985) In vivo reexpression of H-2 antigens in B16 melanoma cells. Exp Clin Immunogenet 2:14\u201323","journal-title":"Exp Clin Immunogenet"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ijc.11497","volume":"108","author":"A Choudhury","year":"2004","unstructured":"Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2\/neu gene, upregulates HLA class I and induces apoptosis of Her2\/neu positive tumor cell lines. Int J Cancer 108:71\u201377","journal-title":"Int J Cancer"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/0008-5472.CAN-2522-2","volume":"64","author":"F Herrmann","year":"2004","unstructured":"Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2\/neu-mediated regulation of components of the MHC class I antigen processing pathway. Cancer Res 64:215\u2013220","journal-title":"Cancer Res"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2004.11.035","volume":"224","author":"BLF Kaplan","year":"2004","unstructured":"Kaplan BLF, Moore TV, Schreiber K, Callender GG, Schreiber H, Nishimura MI (2004) A new murine model for studying HLA-A2-restricted anti-tumor immunity. Cancer Lett 224:153\u2013166","journal-title":"Cancer Lett"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.0.CO;2-C","volume":"78","author":"K Kono","year":"1998","unstructured":"Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER2\/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78:202\u2013208","journal-title":"Int J Cancer"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4049\/jimmunol.159.3.1336","volume":"159","author":"Y Nagata","year":"1997","unstructured":"Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Kanematsu T, Shiku H (1997) Peptides derived from a wild-type murine proto-oncogene c-erbB-2\/HER2\/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336\u20131343","journal-title":"J Immunol"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00043426-200301000-00007","volume":"25","author":"H Zhou","year":"2003","unstructured":"Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2\/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25:27\u201332","journal-title":"J Pediatr Hematol Oncol"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000058533","volume":"60","author":"T Akatsuka","year":"2001","unstructured":"Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S (2001) Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 60:361\u2013366","journal-title":"Oncology"},{"key":"50_CR24","first-page":"788","volume":"8","author":"DG Thomas","year":"2002","unstructured":"Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L (2002) Absence of HER2\/neu gene expression in osteosarcoma and skeletal Ewing\u2019s sarcoma. Clin Cancer Res 8:788\u2013793","journal-title":"Clin Cancer Res"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1349-7006.2000.tb00937.x","volume":"91","author":"K Harada","year":"2000","unstructured":"Harada K, Yamada A, Mine T, Kawagoe N, Takasu H, Itoh K (2000) Mouse homologue of the human SART3 gene encoding tumor-rejection antigen. Jpn J Cancer Res 91:239\u2013247","journal-title":"Jpn J Cancer Res"},{"key":"50_CR26","first-page":"29","volume":"17","author":"H Ishida","year":"2000","unstructured":"Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K (2000) Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol 17:29\u201332","journal-title":"Int J Oncol"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0736-0266(00)90031-7","volume":"19","author":"N Tsuda","year":"2001","unstructured":"Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A (2001) Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19:346\u2013351","journal-title":"J Orthop Res"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/eji.1830230905","volume":"23","author":"JG Houbiers","year":"1993","unstructured":"Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072\u20132077","journal-title":"Eur J Immunol"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/eji.1830250625","volume":"25","author":"S Gnjatic","year":"1995","unstructured":"Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J (1995) Mapping and ranking of potential cytotoxic T epitopes in the p53 protei: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 25:1638\u20131642","journal-title":"Eur J Immunol"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.4049\/jimmunol.165.10.5938","volume":"165","author":"TK Hoffmann","year":"2000","unstructured":"Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB (2000) Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165:5938\u20135944","journal-title":"J Immunol"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.168.3.1338","volume":"168","author":"TK Hoffmann","year":"2002","unstructured":"Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB (2002) The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol 168:1338\u20131347","journal-title":"J Immunol"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ijc.10375","volume":"99","author":"PA Wurtzen","year":"2002","unstructured":"Wurtzen PA, Claesson MH (2002) A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 99:568\u2013572","journal-title":"Int J Cancer"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1084\/jem.186.5.695","volume":"186","author":"MP Vierboom","year":"1997","unstructured":"Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695\u2013704","journal-title":"J Exp Med"},{"issue":"Pt 3","key":"50_CR34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/bj3520611","volume":"352","author":"P Brooks","year":"2000","unstructured":"Brooks P, Murray RZ, Mason GG, Hendil KB, Rivett AJ (2000) Association of immunoproteasomes with the endoplasmic reticulum. Biochem J 352(Pt 3):611\u2013615","journal-title":"Biochem J"},{"issue":"Pt 1","key":"50_CR35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1042\/bj3460155","volume":"346","author":"P Brooks","year":"2000","unstructured":"Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, Tanaka K, Dyson J, Rivett J (2000) Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 346(Pt 1):155\u2013161","journal-title":"Biochem J"},{"key":"50_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0952-7915(99)80014-4","volume":"11","author":"K Fruh","year":"1999","unstructured":"Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76\u201381","journal-title":"Curr Opin Immunol"},{"key":"50_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60885-8","volume":"64","author":"K Tanaka","year":"1997","unstructured":"Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N (1997) Proteasomes and antigen processing. Adv Immunol 64:1\u201338","journal-title":"Adv Immunol"},{"key":"50_CR38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.163.2.1037","volume":"163","author":"Y Rongcun","year":"1999","unstructured":"Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2\/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037\u20131044","journal-title":"J Immunol"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0952-7915(00)00197-7","volume":"13","author":"BJ Eynde Van den","year":"2001","unstructured":"Van den Eynde BJ, Morel S (2001) Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13:147\u2013153","journal-title":"Curr Opin Immunol"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ijc.11654","volume":"109","author":"JA Lindencrona","year":"2004","unstructured":"Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R (2004) CD4+ T cell-mediated HER-2\/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259\u2013264","journal-title":"Int J Cancer"},{"key":"50_CR41","first-page":"880","volume":"61","author":"RT Reilly","year":"2001","unstructured":"Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM (2001) The collaboration of both humoral and cellular HER-2\/neu-targeted immune responses is required for the complete eradication of HER-2\/neu-expressing tumors. Cancer Res 61:880\u2013883","journal-title":"Cancer Res"},{"key":"50_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ijc.20536","volume":"113","author":"P Gallo","year":"2005","unstructured":"Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P (2005) Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113:67\u201377","journal-title":"Int J Cancer"},{"key":"50_CR43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1172\/JCI11752","volume":"107","author":"KL Knutson","year":"2001","unstructured":"Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477\u2013484","journal-title":"J Clin Invest"},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0198-8859(02)00401-9","volume":"63","author":"KL Knutson","year":"2002","unstructured":"Knutson KL, Disis ML (2002) Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2\/neu after active immunization in an ovarian cancer patient. Hum Immunol 63:547\u2013557","journal-title":"Hum Immunol"},{"key":"50_CR45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X","volume":"77","author":"PL Lollini","year":"1998","unstructured":"Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, Musiani P, Muller WJ, Nanni P (1998) Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2\/neu transgenic mice. Int J Cancer 77:937\u2013941","journal-title":"Int J Cancer"},{"key":"50_CR46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1007267814251","volume":"217","author":"A Castilleja","year":"2001","unstructured":"Castilleja A, Ward NE, O\u2019Brian CA, Swearingen B II, Swan E, Gillogly MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG (2001) Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem 217:21\u201333","journal-title":"Mol Cell Biochem"},{"key":"50_CR47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<221::AID-IJC14>3.0.CO;2-L","volume":"70","author":"F Hartmann","year":"1997","unstructured":"Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID (1997) Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2\/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer 70:221\u2013229","journal-title":"Int J Cancer"},{"key":"50_CR48","doi-asserted-by":"crossref","first-page":"26625","DOI":"10.1074\/jbc.M003114200","volume":"275","author":"O Tikhomirov","year":"2000","unstructured":"Tikhomirov O, Carpenter G (2000) Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 275:26625\u201326631","journal-title":"J Biol Chem"},{"key":"50_CR49","first-page":"3904","volume":"60","author":"SL Kominsky","year":"2000","unstructured":"Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM (2000) Down-regulation of neu\/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 60:3904\u2013398","journal-title":"Cancer Res"},{"key":"50_CR50","first-page":"7037","volume":"50","author":"C Marth","year":"1990","unstructured":"Marth C, Muller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE, Daxenbichler G (1990) Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50:7037\u20137041","journal-title":"Cancer Res"},{"key":"50_CR51","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910580415","volume":"58","author":"S Mishra","year":"1994","unstructured":"Mishra S, Hamburger AW (1994) Interferon gamma-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells. Int J Cancer 58:538\u2013542","journal-title":"Int J Cancer"},{"key":"50_CR52","doi-asserted-by":"crossref","first-page":"10746","DOI":"10.1016\/S0021-9258(18)87010-7","volume":"265","author":"RJ Epstein","year":"1990","unstructured":"Epstein RJ, Druker BJ, Roberts TM, Stiles CD (1990) Modulation of a Mr 175,000 c-neu receptor isoform in G8\/DHFR cells by serum starvation. J Biol Chem 265:10746\u201310751","journal-title":"J Biol Chem"},{"key":"50_CR53","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/S0021-9258(19)39772-8","volume":"265","author":"SS Huang","year":"1990","unstructured":"Huang SS, Koh HA, Konish Y, Bullock LD, Huang JS (1990) Differential processing and turnover of the oncogenically activated neu\/erb B2 gene product and its normal cellular counterpart. J Biol Chem 265:3340\u20133346","journal-title":"J Biol Chem"},{"key":"50_CR54","first-page":"929","volume":"9","author":"A Castilleja","year":"2002","unstructured":"Castilleja A, Ward NE, Epstein RB, Kudelka AP, Gershenson DM, Efferson CL, O\u2019Brian CA, Ioannides CG (2002) Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro. Oncol Rep 9:929\u2013935","journal-title":"Oncol Rep"},{"key":"50_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/stem.150001","volume":"15","author":"DM Reese","year":"1997","unstructured":"Reese DM, Slamon DJ (1997) HER-2\/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1\u20138","journal-title":"Stem Cells"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-005-0050-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0050-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T14:25:54Z","timestamp":1706538354000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-005-0050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s00262-005-0050-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,6]]}}}